JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257874

Human CBR1 knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

CBR1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.
2 Images
Western blot - Human CBR1 knockout A549 cell lysate (AB257874)
  • WB

Lab

Western blot - Human CBR1 knockout A549 cell lysate (AB257874)

Lane 1 : Wild-type A549 cell lysate (20 ug)
Lane 2 : CBR1 knockout A549 cell lysate (20 ug)
Lane 3 : HeLa cell lysate (20 ug)

Lanes 1-3 : Merged signal (red and green). Green - ab156590 observed at 30 kDa. Red - loading control ab8245 observed at 36 kDa.

ab156590 Anti-CBR1 antibody [EPR9660] was shown to specifically react with CBR1 in wild-type A549 cells. Loss of signal was observed when knockout cell line ab266954 (knockout cell lysate ab257874) was used. Wild-type and CBR1 knockout samples were subjected to SDS-PAGE. ab156590 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CBR1 antibody [EPR9660] (<a href='/en-us/products/primary-antibodies/cbr1-antibody-epr9660-ab156590'>ab156590</a>) at 1/1000 dilution

Lane 1:

Wild-type A549 cell lysate at 20 µg

Lane 2:

CBR1 knockout A549 cell lysate at 20 µg

Lane 2:

Western blot - Human CBR1 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-cbr1-knockout-a549-cell-line-ab266954'>ab266954</a>)

Lane 3:

HeLa cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 30 kDa

Observed band size: 30 kDa

false

Sanger Sequencing - Human CBR1 knockout A549 cell lysate (AB257874)
  • Sanger seq

Unknown

Sanger Sequencing - Human CBR1 knockout A549 cell lysate (AB257874)

Homozygous : 1 bp insertion in exon1

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

Disease

Carcinoma

style
left-column

Complementary Products

Proteins & Peptides

AB259412

Recombinant human VEGF 165A protein (Active)

Premium Bioactive

Mass Spectrometry - Recombinant human VEGF 165A protein (Active) (AB259412)

  • 0
  • 0
Primary Antibodies

AB156590

Anti-CBR1 antibody [EPR9660]

RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBR1 antibody [EPR9660] (AB156590)

  • 0
  • 0
Proteins & Peptides

AB180319

Recombinant Human RPL18A protein (denatured)

SDS-PAGE - Recombinant Human RPL18A protein (denatured) (AB180319)

  • 0
  • 0
Proteins & Peptides

AB288799

Recombinant Human VCAM1 protein (Active)

Premium Bioactive

Biological Activity - Recombinant Human VCAM1 protein (Active) (AB288799)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257874-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human CBR1 knockout A549 cell lysate", "number":"AB257874-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB257874-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
CBR1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cbr1 also known as carbonyl reductase 1 is an important enzyme in the reduction of carbonyl compounds to their alcohol forms. It weighs around 30 kDa and exhibits a wide expression across various tissues but is notably present in the liver and heart. The enzyme acts as a monomer and follows an NADPH-dependent mechanism for its action playing an important role in the detoxification of xenobiotics and the metabolism of endogenous compounds.
Biological function summary

Carbonyl reductase 1 functions in the metabolism of prostaglandins steroids and aromatic aldehydes. Cbr1 is not known to form part of a larger protein complex but acts independently to execute its enzymatic roles. It exhibits broad substrate specificity allowing it to reduce a variety of carbonyl groups which influences several physiological processes such as lipid metabolism and hormone synthesis.

Pathways

The enzyme plays an important role in the prostaglandin metabolic pathway where it reduces prostaglandin E2. Additionally Cbr1 interacts within the retinol metabolism pathway. In these pathways it functions alongside proteins such as aldo-keto reductases and aldose reductase sharing substrate specificity which impacts cellular responses and metabolic regulation.

Cbr1 influences the development of drug resistance in cancer therapy particularly in anthracycline-treated cancers due to its role in drug metabolism. It also associates with cardiovascular conditions where its metabolic activity might affect oxidative stress levels. Connections with other proteins such as superoxide dismutases link Cbr1 to oxidative stress response pathways impacting disease progression and therapy outcomes.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com